Inactive Instrument

US-China Biomedical Technology, Inc.

Equities

UCBB

US91734Q1040

Healthcare Facilities & Services

Us-China Biomedical Technology, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2018

January 10, 2019 at 10:25 am EST

US-China Biomedical Technology, Inc. announced earnings results for the third quarter ended November 30, 2018. For the third quarter, the company announced operating loss was USD 119,345 compared to USD 128,969 a year ago. Net loss was USD 119,345 compared to USD 131,552 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, operating loss was USD 348,906 compared to USD 398,883 a year ago. Net loss was USD 536,958 compared to USD 406,466 a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.03 a year ago.

Latest news about US-China Biomedical Technology, Inc.

US China Biomedical Technology : China stocks rise after Sino-U.S. 'candid' talks; Hong Kong gains	21-09-10	RE
Safran : Boeing faces rocky path to gaining approval for 737 MAX return in China	21-06-23	RE
Analysis: Delay to U.S. China investment ban leaves U.S. investors in limbo	21-02-01	RE
Us-China Biomedical Technology, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2019	19-07-22	CI
Us-China Biomedical Technology, Inc. Reports Earnings Results for the Full Year Ended February 28, 2019	19-06-12	CI
US-China Biomedical Technology, Inc. Receives Resignation of Wentie Sun as a Member of the Board	19-06-12	CI
Safa Movassaghi Resigns as Vice President and Joins as Member of the Board of US-China Biomedical Technology, Inc	19-03-22	CI
Us-China Biomedical Technology, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2018	19-01-10	CI
US-China Biomedical Reportedly Intends To Seek Acquisitions	19-01-10	CI
US-China Biomedical Technology, Inc. Announces Resignation of Rand Scott as Member of the Board	19-01-07	CI
US-China Biomedical Technology, Inc. Appoints Safa Movassaghi as Vice President	18-11-07	CI
US-China Biomedical Technology, Inc. Appoints Wentie Robert Sun as a Member of Board	18-09-04	CI
US-China Biomedical Technology, Inc. Appoints H. Rand Scott as a Member of the Board	18-07-18	CI
Cloud Security Corporation will Change its Name to US-China Biomedical Technology, Inc	18-01-30	CI
Cloud Security Corporation Announces Resignation of Amanda Huang as Senior Vice President	18-01-11	CI
Cloud Security Corporation Announces Management Changes	17-12-01	CI
US-China Biomedical Technology, Inc. announced that it has received $0.05 million in funding	17-09-20	CI
Cloud Security Corporation announced a financing transaction	17-09-13	CI
Cloud Security Corporation Announces Executive Changes	17-08-01	CI
Michael R. Dunn completed the acquisition of 92.12% stake in Cloud Security Corporation from Goldenrise Development, Inc.	17-07-27	CI
Michael R. Dunn signed a definitive agreement to acquire 92.12% stake in Cloud Security Corporation from Goldenrise Development, Inc. for $0.36 million.	17-06-29	CI
Cloud Security Corporation Announces Management Changes	17-06-23	CI
Zhi Lu Peng cancelled the acquisition of 92% stake in Cloud Security Corporation from Goldenrise Development, Inc.	17-06-14	CI
Cloud Security Corporation Enters into Letter of Intent with Five Branches University for the Development and Design of Wellness Bio Spas Incorporating Eastern and Western Medicine	17-04-12	CI
Zhi Lu Peng entered into an agreement to acquire 92% stake in Cloud Security Corporation from Goldenrise Development, Inc. for $0.4 million.	17-04-03	CI

Chart US-China Biomedical Technology, Inc.

Duration

Period

Chart US-China Biomedical Technology, Inc.

More charts

Company Profile

US-China Biomedical Technology, Inc, formerly Cloud Security Corporation, is focused on integrating and developing synergistic relationships with doctors and hospitals. The Company focuses on developing a scalable biomedical bridge that connects patients and bio-technology advances in China with the Company's network of United States-based doctors and hospitals. The bridge provides concierge and general medical services for patients moving from China to the United States. Its concierge services are for cancer patient referrals that are in non-critical, non-life threatening positions, pre-screening and genetic testing for family members of cancer patients, and patients suffering from diabetes. Its general medical care services also include preventative care and physicals.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
EUROFINS SCIENTIFIC SE	-3.97%	11.66B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
PURE HEALTH HOLDING	-31.75%	11.77B

Other Healthcare Facilities & Services